RNS Number : 1458T
Biome Technologies PLC
13 November 2023
 

This announcement contains inside information for the purposes of Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication of this announcement, this information is now considered to be in the public domain.

 

13 November 2023

 

Biome Technologies plc

("Biome", the "Company" or the "Group")

 

Trading Update

 

Biome Technologies plc, a leading bioplastics and radio frequency technology business, today provides an unaudited trading update for the quarter ended 30 September 2023.

 

Group revenues for the nine months to 30 September 2023 were £5.2m, a 19.6% increase over the same period last year (2022 Q3 YTD: £4.3m). The results are in line with management expectations. Performance in 2023 Q3 reflects lower revenue recognition in the RF Technologies division, offset by an increase in revenues from the Bioplastics division where, year-to-date, we are seeing a strong improvement in trading.

 

The Group had a cash balance at 30 September 2023 of £0.9m (30 September 2022: £0.65m) and had 2026 convertible loan notes outstanding of £0.85m and no bank debt.

 

Bioplastics Division

 

The division's revenues in 2023 Q3 were £1.3m, an 18% increase on 2022 Q3 (2022 Q3: £1.2m). 2023 year to date revenues were £4.4m, 36% ahead of the prior year (2022 Q3 YTD: £3.2m).

 

The Bioplastics division is seeing continued success, particularly in North American markets. Several new customers, particularly for packaging films, have been adopting our materials and are initiating larger volume manufacturing. We have also seen increased demand from more established customers than in 2022. We are seeing some variation in quarterly demand as our newer customers ramp up their production.  However, we believe that the breadth of customers and applications is taking us towards a more resilient business model.

 

RF Technologies Division

 

Revenues in the RF Technologies division for 2023 Q3 were £0.3m, compared to £0.7m in Q3 2022 and in line with 2023 Q2 (2023 Q2: £0.3m). Revenues for the nine months to 30 September 2023 were £0.8m (2022 Q3 YTD: £1.1m).

 

The division continues to be in extended discussions with several potential customers regarding contracts that would have revenue and profit recognition potential of significance for 2024.

 

Management is pleased with the novel market sectors in which the division is building a pipeline of potential new business and the scale of some of these opportunities. We remain cautious on the precise timing of converting these opportunities into orders and the associated revenue recognition, as much of this work requires considerable new collaborative designs with customers.

 

Group Outlook

 

The Board is pleased with the strong progress of the Bioplastics division which continues to grow. It is particularly encouraging to see the ongoing diversification of the customer base that will provide a broader platform for potential growth in due course in line with our stated strategy.

 

The RF Technologies division's team is working hard to convert the pipeline of sizable opportunities they have building. Detailed contract discussions on several projects are proving extended and some uncertainty as to timing remains.

 

The Board remains confident in its revenue expectations for the Group as a whole due, in particular, to the robust performance of the Bioplastics division. However, the finalisation of discussions in relation to two of the RF division's projects, whilst progressing and expected to complete in due course, is taking longer to finalise than originally expected. As a result, and given the proximity to the year-end, there is an increasing risk that these delays will impact on the level of adjusted LBITA and cash receipts in the 2023 financial year.  Whilst this is not the position the Board would have wished for, it remains confident that these two projects will be delivered, albeit now in the 2024 financial year.

 

 

 

-Ends-

 

For further information please contact:

Biome Technologies plc

Paul Mines, Chief Executive Officer

Rob Smith, Chief Financial Officer

www.biometechnologiesplc.com

Tel: +44 (0) 2380 867 100

 

Allenby Capital

David Hart/Alex Brearley (Nominated Adviser)

Kelly Gardiner/Tony Quirke (Sales and Corporate Broking)

www.allenbycapital.com

Tel: +44 (0) 20 3328 5656

 

About Biome

Biome Technologies plc is an AIM listed, growth-orientated, commercially driven technology group. Our strategy is founded on building market-leading positions based on patented technology and serving international customers in valuable market sectors. We have chosen to do this by developing products in application areas where the value-added pricing can be justified and are not reliant on government legislation. These products are driven by customer requirements and are compatible with existing manufacturing processes. They are market rather than technology-led.

 

The Group comprises two divisions, Biome Bioplastics and RF Technologies.

 

Biome Bioplastics is a leading developer of highly-functional, bio-based and biodegradable plastics. The company's mission is to produce bioplastics that challenge the dominance of oil- based polymers.

 

RF Technologies designs, builds and services advanced radio frequency (RF) systems. Dielectric and induction heating products are at the core of a product offering that ranges from portable sealing devices to large furnaces for the fibre optics and other industrial markets.

 

www.biometechnologiesplc.com www.biomebioplastics.com and www.thinkbioplastic.com www.stanelcorftechnologies.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTNKKBKOBDDNDD